The role of new therapies for severe community-acquired pneumonia

Current Opinion in Infectious Diseases

Volumn 19, Issue 6, 2006, Pages 557-564

  Restrepo, Marcos I ^a,b   Anzueto, Antonio ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Veterans Evidence Based Research Dissemination Implementation Center   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

Antibiotics; Community acquired pneumonia; Streptococcus pneumoniae

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CLARITHROMYCIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN;

COMMUNITY ACQUIRED PNEUMONIA; DIAGNOSTIC TEST; DISEASE SEVERITY; HOSPITAL COST; HOSPITALIZATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; MORTALITY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; RISK FACTORS;

EID: 33750526032     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3280106b7f     Document Type: Review

References (103)

1. Centers for Disease Control and Prevention. Pneumonia and influenza death rates - United States, 1979-1994. MMWR Morb Mortal Wkly Rep 1995; 44:535-537. [Erratum in MMWR Morb Mortal Wkly Rep 1995; 44:782].
2. National Center for Health Statistics CfDCaP. Advance report of final mortality statistics 1992. Hyattsville, MD: US Department of Health and Human Services, Public Health Service; 1994.
3. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-1754.
4. European Respiratory Society. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998; 11:986-991.
5. Huchon G, Woodhead M. Management of adult community-acquired lower respiratory tract infections. Eur Respir Rev 1998; 8:391-426.
6. Mandell LA, Marrie TJ, Grossman RF, et al., The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000; 31:383-421.
7. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37:1405-1433.
8. Bartlett JG, Dowell SF, Mandell LA, et al., Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-382.
9. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160:1399-1408.
10. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26:1138-1180. These are the most recent guidelines publish by both the European Respiratory and Microbiological societies. These guidelines use evidence-based medicine to grade their recommendations. The treatment recommendations take into consideration the emergence of resistance pathogens.
11. Kozak LJ, Hall MJ, Owings MF. National Hospital Discharge Survey 2000: annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2002; 153:1-194.
12. Marston BJ, Plouffe JF, File TM Jr, et al., The Community-Based Pneumonia Incidence Study Groups. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio . Arch Intern Med 1997; 157:1709-1718.
13. Minino AM, Arias E, Kochanek KD, et al. Deaths: final data for 2000. Natl Vital Stat Rep 2002; 50:1-119.
14. Halm EA, Teirstein AS. Clinical practice management of community-acquired pneumonia. N Engl J Med 2002; 347:2039-2045.
15. Leroy O, Santre C, Beuscart C, et al. A five-year study of severe community-acquired pneumonia with emphasis on prognosis in patients admitted to an intensive care unit. Intensive Care Med 1995; 21:24-31.
16. Moine P, Vercken JB, Chevret S, et al., French Study Group for Community-Acquired Pneumonia in the Intensive Care Unit. Severe community-acquired pneumonia: Etiology, epidemiology, and prognosis factors. Chest 1994; 105:1487-1495.
17. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: Epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144:312-318.
18. Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis [comment]. J Am Med Assoc 1996; 275:134-141.
19. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166:717-723.
20. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20:820-837.
21. Gutierrez F, Masia M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia in adult patients at the dawn of the 21st century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005; 11:788-800. This is a prospective study that reports the epidemiology, microbiology and treatment in a cohort of CAP patients evaluated in Spain.
22. Friedman ND, Kaye KS, Stout JE, et al. Healthcare-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791-797.
23. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33:158-165.
24. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20:14-19.
25. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118:1344-1354.
26. Meehan TP, Chua-Reyes JM, Tate J, et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117:1378-1385.
27. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296-301.
28. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-3862. This is a report of healthcare-associated pneumonia and proved extensive epidemiological and outcome data. Many of these patients are severely ill and required ICU care. The study includes patients from nursing home and long-term facilities.
29. Feldman C, Viljoen E, Morar R, et al. Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology 2001; 6:323-330.
30. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000; 31:1066-1078.
31. Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. J Am Med Assoc 2005; 294:2712-2719. [See comment].
32. Tejerina E, Frutos-Vivar F, Restrepo MI, et al., International Mechanical Ventilation Study G. Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 2005; 20:230-238. This is a report of a large cohort of CAP patients requiring mechanical ventilation. The study describes the epidemiology, mode of mechanical ventilation, complications and outcome of CAP patients requiring mechanical ventilation.
33. Marrie TJ, Carriere KC, Jin Y, Johnson DH. Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. Clin Infect Dis 2003; 36:413-421.
34. Pascual FE, Matthay MA, Bacchetti P, Wachter RM. Assessment of prognosis in patients with community-acquired pneumonia who require mechanical ventilation. Chest 2000; 117:503-512.
35. Mehta R, Groth M. Clinical application of a prognostic model for severe community-acquired pneumonia. Chest 2001; 119:312-313.
36. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. J Am Med Assoc 1997; 278:2080-2084.
37. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 2002; 162:1059-1064.
38. Dean NC, Suchyta MR, Bateman KA, et al. Implementation of admission decision support for community-acquired pneumonia. Chest 2000; 117:1368-1377.
39. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-250.
40. Marrie TJ, Lau CY, Wheeler SL, et al., CAPITAL Study Investigators Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. A controlled trial of a critical pathway for treatment of community-acquired pneumonia . J Am Med Assoc 2000; 283:749-755.
41. Ewig S, Schafer H, Torres A. Severity assessment in community-acquired pneumonia. Eur Respir J 2000; 16:1193-1201.
42. Ewig S, Ruiz M, Mensa J, et al. Severe community-acquired pneumonia: Assessment of severity criteria. Am J Respir Crit Care Med 1998; 158:1102-1108.
43. The British Thoracic Society. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital. Br J Hosp Med 1993; 49:346-50.
44. Lim WS, Lewis S, Macfarlane JT. Severity prediction rules in community acquired pneumonia: a validation study. Thorax 2000; 55:219-223.
45. British Thoracic Society. Guidelines for the management of community acquired pneumonia in childhood. Thorax 2002; 57 (Suppl 1):i1-24.
46. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377-382.
47. Metlay JP, Fine MJ. Testing strategies in the initial management of patients with community-acquired pneumonia. Ann Intern Med 2003; 138:109-118.
48. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118:384-392. This is a recent prospective evaluation of validated predictor rules in order to identify which patients can be safely treated as outpatients or require hospitalization.
49. Capelastegui A, Espana PP, Quintana JM, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 2006; 27:151-157. This is a report of a large prospective cohort of CAP patients. The investigators validate the predictive rules for management.
50. Ewig S, de Roux A, Bauer T, et al. Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 2004; 59:421-427.
51. Espana PP, Capelastegui A, Quintana JM, et al. A prediction rule to identify allocation of inpatient care in community-acquired pneumonia. Eur Respir J 2003; 21:695-701.
52. Arnold FW, Ramirez JA, McDonald LC, Xia EL. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003; 124:121-124.
53. Ewig S, Kleinfeld T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999; 14:370-375.
54. Farr BM, Sloman AJ, Fisch MJ. Predicting death in patients hospitalized for community-acquired pneumonia [comment]. Ann Intern Med 1991; 115:428-436.
55. Karalus NC, Cursons RT, Leng RA, et al. Community acquired pneumonia: aetiology and prognostic index evaluation. Thorax 1991; 46:413-418.
56. Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51:1010-1016.
57. Niederman MS, Bass JB Jr, Campbell GD, et al., American Thoracic Society Medical Section of the American Lung Association. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148:1418-1426.
58. Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004; 32:2398-2402.
59. Cordero E, Pachon J, Rivero A, et al., The Grupo Andaluz para el Estudio de las Enfermedades Infecciosas. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: validation of severity criteria. Am J Respir Crit Care Med 2000; 162:2063-2068.
60. Levin KP, Hanusa BH, Rotondi A, et al. Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. J Gen Intern Med 2001; 16:590-598.
61. Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123:174-180.
62. Boussekey N, Leroy O, Georges H, et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005; 33:257-263. Several investigators have identified procalcitonin as a potential marker for severity in CAP patients. This study is a prospective validation in a cohort of patients requiring ICU care.
63. van der Meer V, Neven AK, van den Broek PJ, Assendelft WJ. Diagnostic value of C reactive protein in infections of the lower respiratory tract: systematic review. Br Med J 2005; 331:26. C-reactive protein is another serum marker shown to be elevated in patients with infection and/or inflammatory process. This is a systematic review of the diagnostic value of C-reactive protein in patients with lower respiratory tract infections.
64. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164:637-644.
65. Restrepo MI, Mortensen EM, Anzueto A, Pugh JA. Mortality in monotherapy versus combination therapy in severe community-acquired pneumonia: a systematic review [abstract]. Chest 2003; 124 (4S):190S.
66. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one-year prospective study of 346 consecutive patients. Thorax 1996; 51:179-184.
67. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160:397-405.
68. El-Solh AA, Sikka P, Ramadan F, Davies J. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163 (3 Pt 1):645-651.
69. Afessa B, Green B. Bacterial pneumonia in hospitalized patients with HIV infection: the Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study. Chest 2000; 117:1017-1022.
70. Shefet D, Robenshtok E, Paul M, Leibovici L. Empirical atypical coverage for inpatients with community-acquired pneumonia: systematic review of randomized controlled trials. Arch Intern Med 2005; 165:1992-2000. This is a report of a systematic review of clinical studies that included empirical atypical coverage in their treatment. This review confirms that patients who receive atypical coverage in their therapy have a better outcome.
71. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-1858.
72. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31:1349-1356.
73. Fogarty C, Siami G, Kholer R, et al. Multicenter, open label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin Infect Dis 2004; 38 (S1):S16-S23.
74. Leroy O, Saux P, Bedos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128:172-183. This is a prospective study that compared monotherapy with combination therapy in critically ill patients. There were no differences in patients' outcomes. It is important to point out that very few patients required mechanical ventilation and or vasopressors.
75. Bodi M, Rodriguez A, Sole-Violan J, et al., Community-Acquired Pneumonia Intensive Care Units Study I. Antibiotic prescription for community-acquired pneumonia in the intensive care unit: impact of adherence to Infectious Diseases Society of America Guidelines on Survival. Clin Infect Dis 2005; 41:1709-1716. This study evaluated the compliance with the guidelines treatment recommendation with outcomes in patients with severe CAP.
76. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110:451-457.
77. Garcia Vazquez E, Mensa J, Martinez JA, et al. Lower mortality among patients with community-acquired pneumonia treated with a macrolide plus a beta-lactam agent versus a beta-lactam agent alone. Eur J Clin Microbiol Infect Dis 2005; 24:190-195. This is a report of a prospective cohort of CAP patients and confirms that combination of a beta-lactam and a macrolide results in better outcome.
78. Mortensen EM, Restrepo M, Anzueto A, Pugh J. Effects of guideline-concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia [see comment]. Am J Med 2004; 117:726-731.
79. Moroney JF, Fiore AE, Harrison LH, et al. Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001; 33:797-805.
80. Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182:840-847.
81. Metlay JP, Hofmann J, Cetron MS, et al. Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000; 30:520-528.
82. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842.
83. Baddour LM, Yu VL, Klugman KP, et al., International Pneumococcal Study G. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444.
84. Lujan M, Gallego M, Fontanals D, et al. Prospective observational study of bacteremic pneumococcal pneumonia: Effect of discordant therapy on mortality [see comment]. Crit Care Med 2004; 32:625-631.
85. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-395.
86. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107 (1A):34S-43S.
87. Sabria M, Pedro-Botet ML, Gomez J, et al., Legionnaires Disease Therapy G. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128:1401-1405. This report confirms that patients with Legionnaires disease can be treated with respiratory fluoroquinolones.
88. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119:1439-1448.
89. Halley HJ. Approaches to drug therapy, formulary, and pathway management in a large community hospital. Am J Health Syst Pharm 2000; 57 (Suppl 3): S17-S21.
90. Yost NP, Bloom SL, Richey SD, et al. An appraisal of treatment guidelines for antepartum community-acquired pneumonia. Am J Obstet Gynecol 2000; 183:131-135.
91. Palmer CS, Zhan C, Elixhauser A, et al. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin. Clin Ther 2000; 22:250-264.
92. Fogarty CM, Greenberg RN, Dunbar L, et al. Effectiveness of levofloxacin for adult community-acquired pneumonia caused by macrolide-resistant Streptococcus pneumoniae: integrated results from four open-label, multicenter, phase III clinical trials. Clin Ther 2001; 23:425-439.
93. Clark LC, Davis CW. Experiences at a large teaching hospital with levo-floxacin for the treatment of community-acquired pneumonia. Am J Health Syst Pharm 2000; 57 (Suppl 3):S10-S13.
94. Menendez R, Perpina M, Torres A. Evaluation of nonresolving and progressive pneumonia. Semin Respir Infect 2003; 18:103-111.
95. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162:154-160.
96. Rhew DC, Tu GS, Ofman J, et al. Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis. Arch Intern Med 2001; 161:722-727.
97. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161:848-850.
98. Eron LJ, Passos S. Early discharge of infected patients through appropriate antibiotic use. Arch Intern Med 2001; 161:61-65.
99. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination coverage among persons aged > or =65 years and persons aged 18-64 years with diabetes or asthma - United States, 2003. MMWR Morb Mortal Wkly Rep 2004; 53:1007-1012. [Erratum in MMWR Morb Mortal Wkly Rep 2004; 54:935].
100. Centers for Disease Control and Prevention. Influenza vaccination levels among persons aged > or =65 years and among persons aged 18-64 years with high-risk conditions - United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 54:1045-1049. Most recent recommendations related to influenza vaccination.
101. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21:2207-2217.
102. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. J Am Med Assoc 1993; 270:1826-1831.
103. Centers for Disease Control and Prevention. Updated recommendations on the use of pneumococcal conjugate vaccine: suspension of recommendation for third and fourth dose. MMWR Morb Mortal Wkly Rep 2004; 53:177-178.